Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can software and expert review unlock curative radiation for Hard-to-Treat cancers?

NCT ID NCT06668038

Disease control Sponsor: Centre Leon Berard Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 16, 2026 · Updated 1 time

Summary

This study evaluates a standardized process for planning repeat radiation therapy in patients with isolated local recurrence, second cancers, or limited metastases. Radiation oncologists and physicists from multiple centers review each case together, using deformable fusion software to sum up doses from previous and planned treatments in equivalent dose 2 gray units. Researchers measure how often this process changes the treatment plan, such as making curative re-irradiation possible or adjusting doses to nearby organs. The study also tracks late side effects and local control at 3 and 6 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
multidisciplinary expert review of re-irradiation plans combined with deformable fusion dose-accumulation software
What this could lead to
If it works, this process could help more patients with recurrent or second cancers receive curative doses of radiation that were previously considered unsafe.
What could go wrong
This is an observational study without a comparison group, so it cannot prove the process improves outcomes. Re-irradiation still carries a risk of serious late side effects, and the software's dose estimates may not always match real tissue effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years when signing the consent form * Re-irradiation with desired curative intent (≥ 50 Gy EQD2), with volume to be irradiated totally or partially included in a previous irradiation field: * Oligo-metastases or oligo-progression (\< 5 metastases in less than 3 sites) * Second cancer * Isolated local recurrence * Life expectancy \> 6 months * Dated and signed informed consent * Affiliation to a social security scheme or equivalent Exclusion Criteria: * Indication of intracranial, prostate, rectum or esophagus re-irradiation * Diagnosis of multi-metastatic cancer * PS ECOG ≥ 2 * Impossibility to interrupt current treatment with a tyrosine kinase inhibitor or other systemic treatment (excluding hormonal therapy) which may potentiate the rays effects (duration of wash-out according to treatment instructions) * Pregnant or breastfeeding women * Tutorship or curatorship or deprivation of liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Radiotherapy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Radiotherapy Re-irradiation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aphp Marseille Chu Timone Et Hopital Nord Marseille

    NOT_YET_RECRUITING

    Marseille, 13005, France

  • Centre Antoine Lacassagne

    NOT_YET_RECRUITING

    Nice, 06189, France

  • Centre Georges Francois Leclerc

    NOT_YET_RECRUITING

    Dijon, 21069, France

  • Centre Leon Berard

    RECRUITING

    Lyon, 69373, France

  • Centre Marie Curie

    NOT_YET_RECRUITING

    Valence, 26000, France

  • Centre de Radiotherapie Du Beaujolais

    NOT_YET_RECRUITING

    Villefranche-sur-Saône, 69655, France

  • Ch Bourg En Bresse

    RECRUITING

    Bourg-en-Bresse, 01012, France

  • Chu Grenoble Alpes

    NOT_YET_RECRUITING

    Grenoble, 38043, France

  • Institut de Cancerologie de L'Ouest

    NOT_YET_RECRUITING

    Angers, 49055, France

  • Institut de Cancerologie de L'Ouest

    NOT_YET_RECRUITING

    Saint-Herblain, 44805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.